Latest News about REGN
Recent news which mentions REGN
   Stock-Split Watch: Are These 2 Top Growth Stocks Next?
   
  
  
  March 28, 2024
  From Motley Fool
 
   3 Biotech Stocks to Buy for the Next Bull Run: March 2024
   
  
  
  March 26, 2024
  From InvestorPlace
 
   FDA Delays Decision For Regeneron's Inaugural Blood Cancer Therapy, Highlights Trial Concerns
   
  
  
  March 25, 2024
  From Benzinga
 From InvestorPlace
 
   The 3 Most Undervalued Biotech Stocks to Buy in March 2024
   
  
  
  March 13, 2024
  From InvestorPlace
 From Benzinga
 From ETF Trends
 From Motley Fool
 
   Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 20 Years
   
  
  
  March 08, 2024
  From Benzinga
 
   2 Biotech Stocks to Buy Hand Over Fist in March
   
  
  
  March 08, 2024
  From Motley Fool
 
   Biotechs on the Rise: 3 Stocks to Buy for a Shot of Profits
   
  
  
  March 04, 2024
  From InvestorPlace
 
   The Analyst Verdict: Regeneron Pharmaceuticals In The Eyes Of 10 Experts
   
  February 27, 2024
  Tickers 
   REGN
  
  
  From Benzinga
 
   Median Drug Prices For Rare Diseases Hit $300K In 2023, Report Highlights Lack of Clear Rationale Behind Escalating Drug Prices
   
  
  
  February 26, 2024
  From Benzinga
 
   Here's How Much $100 Invested In Regeneron Pharmaceuticals 20 Years Ago Would Be Worth Today
   
  
  
  February 26, 2024
  From Benzinga
 
   (REGN) - Analyzing Regeneron Pharmaceuticals's Short Interest
   
  February 22, 2024
  Tickers 
   REGN
  
  
  From Benzinga
 
   2 No-Brainer Biotech Stocks to Buy Right Now
   
  
  
  February 21, 2024
  From Motley Fool
 From Benzinga
 
   2 Top Growth Stocks to Buy With $1,000 Right Now
   
  
  
  February 18, 2024
  From Motley Fool
 
   10 Health Care Stocks Whale Activity In Today's Session
   
  
  
  February 12, 2024
  From Benzinga
 
   These 2 Stocks Are Trying to Ride the Ozempic Bandwagon: Are They Buys?
   
  
  
  February 09, 2024
  From Motley Fool
 From InvestorPlace
 
   4D Molecular Therapeutics' 4D-150 Phase 2 Data Met Investor Expectations, Analyst Boosts Forecast
   
  
  
  February 06, 2024
  From Benzinga
 
   $100 Invested In This Stock 20 Years Ago Would Be Worth $6,400 Today
   
  
  
  February 06, 2024
  From Benzinga
 
   Cantor Fitzgerald Maintains Neutral Rating for Regeneron Pharmaceuticals: Here's What You Need To Know
   
  February 06, 2024
  Tickers 
   REGN
  
  
  From Benzinga
 
   Stock-Split Watch: Could These 2 Market-Beaters Be Next?
   
  
  
  February 06, 2024
  From Motley Fool
 
   Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
  
  
 Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
  © 2025 FinancialContent. All rights reserved.
 
